Bristol Vanlev
Executive Summary
Omapatrilat OCTAVE hypertension study analysis is expected in late summer or early fall, Bristol says, following company's decision to maintain blinding until all patients have completed the 24 weeks of treatment. In July, the company projected that the data would be available for analysis by late in the second quarter (1"The Pink Sheet" July 31, 2000, p. 21)